{"id":"biomarker-quality-nsclc-2026-05","signal":"Biomarker quality","context":"NSCLC · Phase II/III","claim":"Genomic-grade biomarker selection raises a program's probability of success.","verdict":"validated","shipped":true,"shippedNote":"Scored in the production engine (2.6.0) for oncology solid tumor at Phase II/III.","effect":"+5.2pp held-out AUC over the structural baseline, stable across cohort sizes. The genomic_validated cohort odds ratio was 5.59 vs the Schwaederle (2016) literature anchor of 1.35 — we ship the lower anchor with the overshoot disclosed.","method":"70/30 stratified held-out backtest, N=85 NSCLC (approvals + failures), paired DeLong.","decision":"Scored: genomic_validated 1.35x / protein_only 0.85x / unselected 1.00x (log-odds, Phase II/III).","evidence":{"json":"/evaluations/verdicts/biomarker-quality-nsclc-2026-05.json"},"related":["/research/backtest-nsclc","/methodology/pos-calibration"],"provenance":{"engine_version":"2.6.0","methodology_version":"methodology@2026-05-28"},"dataset_version":"drug-specific-signals@2026-Q3","as_of":"2026-05-28","status":"current"}